Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

Nanchahal J., Ball C., Rombach I., Williams L., Kenealy N., Dakin H., O'Connor H., Davidson D., Werker P., Dutton SJ., Feldmann M., Lamb SE.

DOI

10.1016/s2665-9913(22)00093-5

Type

Journal article

Journal

The Lancet Rheumatology

Publisher

Elsevier BV

Publication Date

06/2022

Volume

4

Pages

e407 - e416

Permalink Original publication